Navigation Links
AMA Grants New Category III CPT Code to Premier Heart's Multifunction CardioGram(TM) (MCG)
Date:7/13/2009

PORT WASHINGTON, N.Y., July 13 /PRNewswire/ -- Premier Heart, LLC today announced that the CPT Editorial Panel of the American Medical Association has granted a CPT Category III code to Premier Heart's Multifunction CardioGram(TM) (MCG) system. MCG is the World's first Internet based, non-invasive, stress, radiation and drug free computational electrophysiologic system used for interactive online diagnosis. The MCG is intended as an aid for bridging physician experts with diagnosing physicians via the web in order to facilitate the making of timely and more accurate diagnoses.

Coronary Artery Disease (CAD) is the leading cause of death worldwide, accounting for over 7 million deaths annually. In 2005, 445,687 Americans died as the direct results of CAD, this year an estimated 1.26 million Americans will have a new or recurrent coronary attack.

"Earlier and more accurate detection is the key to preventing advanced heart disease and premature deaths such as NBC's Tim Russert and cable TV's Billy Mays," said Joseph Shen, M.D., founder and co-developer of the MCG technology. "Because of its fundamentally unconventional mathematical approach MCG represents a paradigm shift in heart disease diagnosis. Its ease of use and better accuracy will save lives and bring much needed cost-savings to the world's cardiovascular healthcare markets."

The following uncompensated endorsements are made by our physician clients:

"Being able to accurately diagnose coronary heart disease in a symptomatic patient without the need for an invasive procedure represents significant progress," said John Strobeck, M.D., cardiologist, Medical Director of the Heart-LungCenter, Hawthorne, NJ, and Co-Editor of the journal Congestive Heart Failure. "The Multifunction CardioGram is able to detect the presence of
'/>"/>

SOURCE Premier Heart, LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Blue Cross Foundation Grants Focus on Improving Immigrant Health
2. Lupus Foundation of America Accepting Letters of Intent for Research Grants on Adult Stem Cell Research and Health-Related Quality of Life in Pediatric Lupus
3. Photos: $8 Million in Asthma Research Grants Awarded to 12 Scientists
4. Kessler Foundation Research Center Awarded More Than Two Million Dollars in Grants
5. Medical Safety Net in Florida to Strengthen with Recent Grants
6. Hartford grants increase support for geriatric social work training
7. Delaware Chancery Court Grants Galil Medical Ltd.s Motion for Expedited Proceeding in Suit Against Endocare
8. One Woman Initiative Announces First Grants to Womens Organizations in Five Nations
9. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
10. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
11. ClearWay Minnesota(SM) Board Approves Four Regional Grants
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 1PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 2PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 1Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 4Back to normal 3A Surgery improves outcomes for spine patients 47438 1Back to normal 3A Surgery improves outcomes for spine patients 47438 2